AbbVie Income from Continuous Operations 2010-2024 | ABBV
AbbVie annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- AbbVie income from continuous operations for the quarter ending September 30, 2024 was $1.564B, a 12.18% decline year-over-year.
- AbbVie income from continuous operations for the twelve months ending September 30, 2024 was $5.133B, a 21.29% decline year-over-year.
- AbbVie annual income from continuous operations for 2023 was $4.873B, a 58.86% decline from 2022.
- AbbVie annual income from continuous operations for 2022 was $11.845B, a 2.56% increase from 2021.
- AbbVie annual income from continuous operations for 2021 was $11.549B, a 149.87% increase from 2020.
AbbVie Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$4,873 |
| 2022 |
$11,845 |
| 2021 |
$11,549 |
| 2020 |
$4,622 |
| 2019 |
$7,882 |
| 2018 |
$5,687 |
| 2017 |
$5,309 |
| 2016 |
$5,953 |
| 2015 |
$5,144 |
| 2014 |
$1,774 |
| 2013 |
$4,128 |
| 2012 |
$5,275 |
| 2011 |
$3,433 |
| 2010 |
$4,178 |
| 2009 |
$4,637 |
AbbVie Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-09-30 |
$1,564 |
| 2024-06-30 |
$1,373 |
| 2024-03-31 |
$1,372 |
| 2023-12-31 |
$824 |
| 2023-09-30 |
$1,781 |
| 2023-06-30 |
$2,027 |
| 2023-03-31 |
$241 |
| 2022-12-31 |
$2,472 |
| 2022-09-30 |
$3,952 |
| 2022-06-30 |
$928 |
| 2022-03-31 |
$4,493 |
| 2021-12-31 |
$4,045 |
| 2021-09-30 |
$3,180 |
| 2021-06-30 |
$769 |
| 2021-03-31 |
$3,555 |
| 2020-12-31 |
$38 |
| 2020-09-30 |
$2,313 |
| 2020-06-30 |
$-739 |
| 2020-03-31 |
$3,010 |
| 2019-12-31 |
$2,801 |
| 2019-09-30 |
$1,884 |
| 2019-06-30 |
$741 |
| 2019-03-31 |
$2,456 |
| 2018-12-31 |
$-1,826 |
| 2018-09-30 |
$2,747 |
| 2018-06-30 |
$1,983 |
| 2018-03-31 |
$2,783 |
| 2017-12-31 |
$52 |
| 2017-09-30 |
$1,631 |
| 2017-06-30 |
$1,915 |
| 2017-03-31 |
$1,711 |
| 2016-12-31 |
$1,391 |
| 2016-09-30 |
$1,598 |
| 2016-06-30 |
$1,610 |
| 2016-03-31 |
$1,354 |
| 2015-12-31 |
$1,517 |
| 2015-09-30 |
$1,239 |
| 2015-06-30 |
$1,366 |
| 2015-03-31 |
$1,022 |
| 2014-12-31 |
$-810 |
| 2014-09-30 |
$506 |
| 2014-06-30 |
$1,098 |
| 2014-03-31 |
$980 |
| 2013-12-31 |
$1,128 |
| 2013-09-30 |
$964 |
| 2013-06-30 |
$1,068 |
| 2013-03-31 |
$968 |
| 2012-12-31 |
$1,540 |
| 2012-09-30 |
$1,585 |
| 2012-06-30 |
$1,267 |
| 2012-03-31 |
$883 |
| 2011-12-31 |
$1,157 |
| 2011-09-30 |
$13 |
| 2011-06-30 |
$1,540 |
| 2011-03-31 |
$723 |
| 2010-12-31 |
|
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$294.353B |
$54.318B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
